Clinical Associate Professor of Medicine
Division of Medical Oncology
Department of Internal Medicine
University of Colorado, Denver
Medical Director, Biosimilars
McKesson Specialty Health
The US Oncology Network
The Woodlands, Texas
Jane Knight Lowe Professor
Division of Clinical Immunology and Rheumatology
Vice Chair, Department of Medicine
Center for Education and Research on Therapeutics
Center for Outcomes, Effectiveness Research and Education
Center of Research Translation in Gout and Hyperuricemia
University of Alabama at Birmingham
Director, Scientific Services
This program is intended for rheumatologists, gastroenterologists, oncologists, endocrinologists, and other healthcare professionals who are involved in the care of patients who may be eligible for treatment with biosimilars.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Clinical Care Options, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This program has been made available online.
Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from March 09, 2017, through March 08, 2018:
1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.
You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.
Concise CCO expert commentary on potential side effects with GLP-1 receptor agonists in patients with type 2 diabetes
Neil Skolnik, MD reviews GLP-1 RAs to address elevated A1C, obesity, and CV risk, plus strategies to improve tolerability, adherence
Hyperglycemia can be a deadly complication for anyone with diabetes, but there are tools that can reduce this risk including GLP-1 medications. Learn more today.
CME commentary: GLP-1 receptor agonists to prevent major cardiovascular adverse events (MACE) in type 2 diabetes (T2D), cardiovascular disease (CVD)